In signing the communiqué, Johnson & Johnson and 15 other life science companies are committing to prioritize the safety, science and accessibility of the potential vaccines, therapeutic medicines or diagnostic tools they are developing to help fight the pandemic.
When you're the CFO of a company, you have a holistic view of how a pandemic can touch every aspect of a business, especially when it's a healthcare company. So we posed inquiring mind questions to Joe Wolk about what the past eight months have been like for him at the financial helm of the company—via a Zoom interview.
Johnson & Johnson (NYSE: JNJ) (the Company) recently announced the launch of its large-scale, pivotal, multi-country Phase 3 trial (ENSEMBLE) for its COVID-19 vaccine candidate, JNJ-78436735, being developed by its Janssen Pharmaceutical Companies.
We’re pleased to announce that based on interim results from our ongoing studies, the Janssen Pharmaceutical Companies of Johnson & Johnson are launching ENSEMBLE, a large-scale, multi-country Phase 3 trial of a single dose of our vaccine candidate.
As schools reopen—and sometimes close again—what have we learned about the risks of in-person learning? Lisa Ling speaks to school nurse Robin Cogan and pediatrician Dr. Sam Maldonado to find answers and debunk myths around kids and COVID-19.
"We were pleased to share new research at this year's virtual Psych Congress, underscoring Alkermes' commitment to addressing the challenges faced by those living with serious mental illness," said Amy O'Sullivan, Vice President, Health Economics and Outcomes Research at Alkermes.
Cascale shares updates on its strategic partnerships with industry stakeholders geared toward shifting the industry into one that gives back more than...
The business landscape is reorienting itself and you can almost hear priorities shifting toward change-readiness and the bigger picture. And in this...
